Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $596.0 million.

  • United Therapeutics' Change in Acquisitions & Divestments rose 16232.39% to $596.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year increase of 4754.37%. This contributed to the annual value of $1.5 billion for FY2024, which is 2808.68% down from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' Change in Acquisitions & Divestments is $596.0 million, which was up 16232.39% from $653.9 million recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Change in Acquisitions & Divestments peaked at $831.8 million during Q1 2024, and registered a low of $131.9 million during Q1 2022.
  • Its 5-year average for Change in Acquisitions & Divestments is $440.4 million, with a median of $431.0 million in 2021.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first tumbled by 7097.27% in 2022, then surged by 43805.91% in 2023.
  • Over the past 5 years, United Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $366.6 million in 2021, then dropped by 26.73% to $268.6 million in 2022, then surged by 96.09% to $526.7 million in 2023, then decreased by 9.25% to $478.0 million in 2024, then rose by 24.69% to $596.0 million in 2025.
  • Its last three reported values are $596.0 million in Q3 2025, $653.9 million for Q2 2025, and $611.7 million during Q1 2025.